|

Cadonilimab Injection Clinical Trials

1 actively recruiting trial

Also known as: AK104, Cadonilimab Injection

Pipeline

Phase 2/3: 1

Top Sponsors

  • RemeGen Co., Ltd.1

Indications

  • Gastroesophageal Junction Adenocarcinoma1
  • Gastric Cancer1
  • Cancer1

Other1 trial

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.